Actinium zadavotide guraxetan not checked

AstraZeneca · AZD2265 · FPI-2265

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“AZD2265 (FPI-2265) will be administered as an intravenous (IV) injection.”In the company’s words, NCT07590934 on ClinicalTrials.gov
Tested for
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Main trialPhase 3
“The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.”In the company’s words, NCT07611110 on ClinicalTrials.gov
Other names
AZD2265 · FPI-2265 · 225Ac-PSMA-I&T

Other drugs for Metastatic Castration-resistant Prostate Cancer

All 194 drugs for Metastatic Castration-resistant Prostate Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 4 Jun 2029 AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Phase 1/2Recruiting 25 Sep 2029 Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Actinium zadavotide guraxetan

Following is part of Solo: you see every change to Actinium zadavotide guraxetan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in